Tango Therapeutics, Inc. (TNGX)

NASDAQ: TNGX · IEX Real-Time Price · USD
8.30 -0.29 (-3.38%)
Jan 21, 2022 4:00 PM EST - Market closed

Company Description

Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer.

Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations.

Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer.

The company was founded in 2017 and is based in Cambridge, Massachusetts.

Tango Therapeutics, Inc.
CountryUnited States
Founded2014
IndustryBiotechnology
SectorHealth Care
Employees83

Contact Details

Address:
100 Binney Street
Cambridge, MA 02142
United States
Phone857 320 4900

Stock Details

Ticker SymbolTNGX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1819133

Key Executives

NamePosition
Dr. Barbara L. Weber M.D.President, Chief Executive Officer and Director
Daniella Beckman CPAChief Financial Officer
Dr. Alan Huang Ph.D.Chief Scientific Officer
Dr. Alan Ashworth FRS, Ph.D.Founder and Member of Scientific Advisory Board
Dr. Levi Garraway M.D., Ph.D.Founder
Dr. William G. Kaelin Jr., M.D.Founder and Member of Scientific Advisory Board
Dr. Timothy K. LuFounder
Dr. Antoni Ribas M.D., Ph.D.Founder and Member of Scientific Advisory Board
Douglas J. Barry Esq., J.D.General Counsel
John C. Ross M.S.Vice President of Human Resources

Latest SEC Filings

DateTypeTitle
Jan 4, 2022SC 13D/AGeneral statement of acquisition of beneficial ownership
Jan 4, 20223Initial statement of beneficial ownership of securities
Dec 10, 20214Statement of changes in beneficial ownership of securities
Dec 10, 20213Initial statement of beneficial ownership of securities
Nov 9, 2021424B3Prospectus [Rule 424(b)(3)]
Nov 9, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 9, 20218-KCurrent report
Nov 3, 20214Statement of changes in beneficial ownership of securities
Nov 1, 20213Initial statement of beneficial ownership of securities
Nov 1, 20213Initial statement of beneficial ownership of securities
View All SEC Filings